US2020129520A1PendingUtilityA1

Combination of brimonidine and timolol for topical ophthalmic use

79
Assignee: ALLERGAN SALES LLCPriority: Apr 19, 2002Filed: May 7, 2019Published: Apr 30, 2020
Est. expiryApr 19, 2022(expired)· nominal 20-yr term from priority
Inventors:Chin-Ming ChangGary J. BeckCynthia C. PrattAmy L. Batoosingh
A61K 9/08A61P 27/00A61K 31/4168A61K 31/535A61K 45/06A61K 31/498A61K 31/5377A61P 27/04A61K 9/0048A61K 47/02A61K 47/186F21V 23/023F21V 23/004A61P 27/06A61P 27/02G02B 6/0073F21V 23/002
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An ophthalmic pharmaceutical composition useful in the treatment of glaucoma or ocular hypertension comprising an effective amount of brimonidine and an effective amount of timolol in a pharmaceutically acceptable carrier thereof. 
     
     
         2 . A composition according to  claim 1 , wherein the concentration of brimonidine is 0.01 to 0.5 percent by weight and the concentration of timolol is 0.1 to 1.0 percent by weight. 
     
     
         3 . A composition according to  claim 1 , wherein the concentration of brimonidine is 0.2 percent by weight and the concentration of timolol is 0.5 percent by weight. 
     
     
         4 . A composition according to  claim 1  further comprising from 0.001% to less than 0.01% benzalkonium chloride. 
     
     
         5 . A composition according to  claim 2  further comprising from 0.001% to less than 0.01% benzalkonium chloride. 
     
     
         6 . A composition according to  claim 3  further comprising from 0.001% to less than 0.01% benzalkonium chloride. 
     
     
         7 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 1  topically to the affected eye. 
     
     
         8 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 2  topically to the affected eye. 
     
     
         9 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 3  topically to the affected eye. 
     
     
         10 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 1  to the affected eye. 
     
     
         11 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 2  to the affected eye. 
     
     
         12 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 3  to the affected eye. 
     
     
         13 . An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for lowering intraocular pressure and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used to for lowering intraocular pressure and wherein said pharmaceutical agent comprises effective amount of brimonidine and an effective amount of timolol. 
     
     
         14 . An article of manufacture according to  claim 13  wherein said effective amount of brimonidine is from 0.01 to 0.5 percent by weight and said effective amount of timolol is from 0.1 to 1.0 percent by weight. 
     
     
         15 . An article of manufacture according to  claim 13  wherein said effective amount of brimonidine is from 0.2 percent by weight and said effective amount of timolol is from 0.5 percent by weight. 
     
     
         16 . An article of manufacture according to  claim 13  wherein said pharmaceutical agent further comprises from 0.001% to less than 0.01% benzalkonium chloride. 
     
     
         17 . An article of manufacture according to  claim 16  further comprising 0.005% benzalkonium chloride. 
     
     
         18 . An article of manufacture according to  claim 14  further comprising 0.005% benzalkonium chloride. 
     
     
         19 . An article of manufacture according to  claim 15  further comprising 0.005% benzalkonium chloride. 
     
     
         20 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 4  topically to the affected eye. 
     
     
         21 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 5  topically to the affected eye. 
     
     
         22 . A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to  claim 6  topically to the affected eye. 
     
     
         23 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 4  to the affected eye. 
     
     
         24 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 5  to the affected eye. 
     
     
         25 . A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to  claim 6  to the affected eye.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.